Transforming Clinical Trials with Open Source Tech

Clinical trials historically struggled with several key inefficiencies, many of which became painfully apparent during the COVID-19 pandemic, such as the traditional paper-based, manual reviews and analyses. The pandemic also showed how rapidly patients can enrol for therapies with broad public support and clinical applicability. However, finding enough clinical trial participants for most trials, particularly for treatments of rare diseases, continues to represent a significant hurdle.

Similarly, the COVID-19 pandemic demonstrated how technology can enable clinical trial efficiencies, such as telemedicine, patient communication, trial enrolment, etc. Excitingly, innovators in the space are looking to open-source software to overcome legacy inefficiencies and address modern biopharmaceutical needs.

Accelerating timelines for the discovery of novel therapies

Drug discovery is a particularly time-consuming process – not to mention expensive. The pre-clinical stage alone can take three to six years. Open-source tools can be invaluable in accelerating clinical trial timelines by fast-tracking the discovery of new therapies, repurposing treatments already on the market, empowering community-driven support between biopharmaceutical and medical device companies, and revamping trial design and participation with a patient-centric focus.

Read the full article here.

Find out how EPAM helps deliver value across the entire spectrum of care with patient-centered solutions that are flexible, scalable and imaginative: https://www.epam.com/industries/life-sciences-and-healthcare